January 22, 2020

Coronavirus therapies slowed by intermittent nature of outbreaks

Medicines and vaccines are in development but exist only in laboratories for now

WEST LAFAYETTE, Ind. — As the COVID-19 coronavirus outbreak causes worldwide concern, Purdue University scientists say control measures are an absolute necessity and that medical treatments for similar disease are on the horizon.

Purdue scientists Andrew Mesecar, Purdue's Walther Professor in Cancer Structural Biology and head of the Department of Biochemistry, and Arun Ghosh, the Ian P. Rothwell Distinguished Professor of Chemistry, have been working to develop both oral medicines and vaccines to fight coronavirus, and over the next two weeks, will be working to test their potential drug molecules on the new coronavirus.

However, any drug that is identified to work on the COVID-19 coronavirus will not be available quickly enough to help patients in the current outbreak. But the researchers hope that they can use the discoveries they make with the current virus to better mitigate future outbreaks.

mesecar-virus Purdue University scientists are developing a drug to fight coronavirus. The drug works by blocking a key enzyme of the virus, preventing it from replicating. (Purdue University image/Andrew Mesecar) Download image

The molecules Mesecar and Ghosh have developed block two of the coronavirus enzymes (proteases), stopping coronavirus from replicating.

"The drug targets we've identified are over 95% identical to the enzyme targets we saw on the SARS virus," Mesecar says.

Mesecar says the science and technology surrounding infectious diseases is moving at an "amazing" rate in 2020.

"In 2002 when the SARS outbreak happened, it took months to get to the point where we are now," he says. "With this outbreak, scientists were able to isolate the virus and sequence the genome in less than two weeks. One week later, an additional 20 genomes were available. In another week or two, we'll be able to begin to see if the virus is mutating."

In identifying drug targets on the coronavirus, they take an anti-viral approach similar to what Ghosh used to develop the anti-HIV drug Darunavir, which is sold under the brand name Prezista.

The conornavirus is a common virus in animals and humans that can cause respiratory symptoms of the common cold and flu — only occasionally are there outbreaks of a more serious, flu-like illness. Beginning in 2002, a coronavirus outbreak caused by the SARS variant of the virus killed more than 750 people worldwide. From 2012 to 2015, the MERS coronavirus, which is more distantly related to SARS than the COVID-19 coronavirus, killed nearly 450 people, according to the World Health Organization.

Coronavirus infections can be more serious in cats and piglets; in both cases it is nearly 100% fatal.

The COVID-19 coronavirus resembles a Sputnik-era satellite covered in antennas, which the scientists refer to as spike proteins. These spikes are thought to look like the rays of the sun or a corona, which is how the coronavirus got its name.

"MERS virus and the SARS virus are more different genetically," Mesecar says. "But the COVID-19 coronavirus is genetically almost identical to the SARS virus and, therefore, it is expected to look and act nearly the same.

The intermittent nature of the outbreaks and the relatively small market for the drug — thousands of patients in an outbreak, instead of millions of patients for some chronic diseases — means that pharmaceutical companies have little incentive to develop the drugs for humans.

Late Friday night (Jan. 17), Mesecar and colleagues at the Center for Structural Genomics of Infectious Disease received the genome of the COVID-19 coronavirus, and he and his team analyzed the genome on Saturday. Mesecar found the genome is almost identical to that of the SARS virus.

"This week we are analyzing the genomes from viruses taken from 20 individual patients, and we'll be looking at those sequences to see if there is any variation in the genetics," he said.

Mesecar collaborates on the virus research with a team of scientists across the United States who make up the Center for Structural Genomics of Infectious Diseases, which is based at Northwestern University's Feinberg School of Medicine. The center is funded by the National Institutes of Health's National Institute of Allergies and Infectious Diseases.

But Mesecar is working to set up a rapid-response system of scientists that could quickly develop drugs during future outbreaks caused by genetic variants of the coronavirus. The goal is to have a library of FDA-approved or almost approved compounds that have been predetermined to work on specific coronaviruses so that when an outbreak appears, medicines can be produced and distributed quickly.

"We will be able to do this within my lifetime," he says.

Writer: Steve Tally. 765-494-9809, steve@purdue.edu, @sciencewriter

Source: Andrew Mesecar, 765-494-1924, amesecar@purdue.edu, @andymesecar

Related websites:

Tony Katz radio interview, 1/22/20 “Should Americans be worried about coronavirus?”

"Purdue researchers successfully target 'Achilies heel' of MERS virus" (2015)

"Purdue MERS experts working on way to block dangerous virus" (2014)

"Purdue researchers seek treatment for new MERS coronavirus" (2013)

"Purdue researcher invents molecule that stops SARS" (2008)


Purdue University scientists are developing a drug to fight coronavirus. The drug works by blocking a key enzyme of the virus, preventing it from replicating. (Purdue University image/Andrew Mesecar)

A publication-quality photo is available at https://news.uns.purdue.edu/images/2020/mesecar-virus.gif

Purdue University, 610 Purdue Mall, West Lafayette, IN 47907, (765) 494-4600

© 2015-22 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by Office of Strategic Communications

Trouble with this page? Disability-related accessibility issue? Please contact News Service at purduenews@purdue.edu.